J90 Stock Overview
Operates as a pharmaceutical technology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NurExone Biologic Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.53 |
| 52 Week High | CA$0.92 |
| 52 Week Low | CA$0.16 |
| Beta | -0.091 |
| 11 Month Change | 40.21% |
| 3 Month Change | 26.19% |
| 1 Year Change | 204.60% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| J90 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 32.5% | -7.0% | -0.4% |
| 1Y | 204.6% | -21.6% | 7.1% |
Return vs Industry: J90 exceeded the German Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: J90 exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| J90 volatility | |
|---|---|
| J90 Average Weekly Movement | 16.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: J90's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: J90's weekly volatility has decreased from 28% to 17% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 12 | Lior Shaltiel | nurexone.com |
NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.
NurExone Biologic Inc. Fundamentals Summary
| J90 fundamental statistics | |
|---|---|
| Market cap | €40.05m |
| Earnings (TTM) | -€3.93m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.7x
P/E RatioIs J90 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J90 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.44m |
| Gross Profit | -US$1.44m |
| Other Expenses | US$2.70m |
| Earnings | -US$4.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.056 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did J90 perform over the long term?
See historical performance and comparison